These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

71 related items for PubMed ID: 15830710

  • 1. Progression of renal damage in the obese Zucker rat in response to deoxycorticosterone acetate-salt-induced hypertension.
    Morrison RG, Carpenter AB, Adams VL, Mangiarua EI, Wehner PS, McCumbee WD.
    Ann Clin Lab Sci; 2005; 35(1):54-65. PubMed ID: 15830710
    [Abstract] [Full Text] [Related]

  • 2. Increased reactive oxygen species contributes to kidney injury in mineralocorticoid hypertensive rats.
    Jin L, Beswick RA, Yamamoto T, Palmer T, Taylor TA, Pollock JS, Pollock DM, Brands MW, Webb RC.
    J Physiol Pharmacol; 2006 Sep; 57(3):343-57. PubMed ID: 17033089
    [Abstract] [Full Text] [Related]

  • 3. DOCA stimulates salt appetite in Zucker rats: effect of dose, synergistic action with central angiotensin II, and obesity.
    Omouessi ST, Falconetti C, Fernette B, Thornton SN.
    Brain Res Bull; 2007 Sep 14; 74(1-3):14-20. PubMed ID: 17683784
    [Abstract] [Full Text] [Related]

  • 4. Effects of soy protein isolate feeding on severe kidney damage in DOCA salt-treated obese Zucker rats.
    Asanoma M, Tachibana N, Hirotsuka M, Kohno M, Watanabe Y.
    J Agric Food Chem; 2012 May 30; 60(21):5367-72. PubMed ID: 22553937
    [Abstract] [Full Text] [Related]

  • 5. Rofecoxib decreases renal injury in obese Zucker rats.
    Dey A, Maric C, Kaesemeyer WH, Zaharis CZ, Stewart J, Pollock JS, Imig JD.
    Clin Sci (Lond); 2004 Dec 30; 107(6):561-70. PubMed ID: 15307815
    [Abstract] [Full Text] [Related]

  • 6. Increased sensitivity of the obese Zucker rat to deoxycorticosterone-salt-induced hypertension.
    Morrison RG, Carpenter AB, Moore SK, Mangiarua EI, Valentovic MA, Walker EM, Wehner PS, Rhoten WB, Touchon RC, McCumbee WD.
    J Hypertens; 2002 Nov 30; 20(11):2247-55. PubMed ID: 12409964
    [Abstract] [Full Text] [Related]

  • 7. Strain differences in the development of hypertension and glomerular lesions induced by deoxycorticosterone acetate salt in mice.
    Hartner A, Cordasic N, Klanke B, Veelken R, Hilgers KF.
    Nephrol Dial Transplant; 2003 Oct 30; 18(10):1999-2004. PubMed ID: 13679473
    [Abstract] [Full Text] [Related]

  • 8. Possible involvement of aminopeptidase A in hypertension and renal damage in Dahl salt-sensitive rats.
    Nomura M, Nomura S, Mitsui T, Suzuki M, Kobayashi H, Ito T, Itakura A, Kikkawa F, Mizutani S.
    Am J Hypertens; 2005 Apr 30; 18(4 Pt 1):538-43. PubMed ID: 15831365
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A moderately high fat diet promotes salt-sensitive hypertension in obese zucker rats by impairing nitric oxide production.
    Morrison RG, Mills C, Moran AL, Walton CE, Sadek MH, Mangiarua EI, Wehner PS, McCumbee WD.
    Clin Exp Hypertens; 2007 Aug 30; 29(6):369-81. PubMed ID: 17729054
    [Abstract] [Full Text] [Related]

  • 12. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
    Klanke B, Cordasic N, Hartner A, Schmieder RE, Veelken R, Hilgers KF.
    Nephrol Dial Transplant; 2008 Nov 30; 23(11):3456-63. PubMed ID: 18515791
    [Abstract] [Full Text] [Related]

  • 13. YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction.
    Nakano R, Kurosaki E, Shimaya A, Kajikawa S, Shibasaki M.
    Eur J Pharmacol; 2006 Nov 07; 549(1-3):185-91. PubMed ID: 16989806
    [Abstract] [Full Text] [Related]

  • 14. N-Acetylcysteine improves renal dysfunction, ameliorates kidney damage and decreases blood pressure in salt-sensitive hypertension.
    Tian N, Rose RA, Jordan S, Dwyer TM, Hughson MD, Manning RD.
    J Hypertens; 2006 Nov 07; 24(11):2263-70. PubMed ID: 17053549
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The 5-hydroxytryptamine2A receptor is involved in (+)-norfenfluramine-induced arterial contraction and blood pressure increase in deoxycorticosterone acetate-salt hypertension.
    Ni W, Fink GD, Watts SW.
    J Pharmacol Exp Ther; 2007 May 07; 321(2):485-91. PubMed ID: 17289838
    [Abstract] [Full Text] [Related]

  • 17. Blood pressure variability, cardiac baroreflex sensitivity and organ damage in experimentally hypertensive rats.
    Wang DS, Xie HH, Shen FM, Cai GJ, Su DF.
    Clin Exp Pharmacol Physiol; 2005 Jul 07; 32(7):545-52. PubMed ID: 16026514
    [Abstract] [Full Text] [Related]

  • 18. Variations in renal arteriolar diameter in deoxycorticosterone acetate-salt hypertensive rats. A microvascular cast study.
    Tojo A, Kimura K, Nanba S, Matsuoka H, Sugimoto T.
    Virchows Arch A Pathol Anat Histopathol; 1990 Jul 07; 417(5):389-93. PubMed ID: 2122585
    [Abstract] [Full Text] [Related]

  • 19. Chronic treatment with mianserin prevents DOCA-salt hypertension in rats--evidence for the involvement of central 5-HT2 receptors.
    Silva AL, Cabral AM, Abreu GR, Pires JG, Bissoli NS, Ramage AG.
    Eur J Pharmacol; 2005 Aug 22; 518(2-3):152-7. PubMed ID: 16014306
    [Abstract] [Full Text] [Related]

  • 20. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
    Pugsley MK.
    Proc West Pharmacol Soc; 2005 Aug 22; 48():35-8. PubMed ID: 16416656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.